TRANSCODE THERAPEUTICS INC (RNAZ) Stock News

USA - NASDAQ:RNAZ - US89357L5012 - Common Stock

15.23 USD

+0.31 (+2.08%)

Last: 10/17/2025, 8:00:01 PM

15.35 USD

+0.12 (+0.79%)

After Hours: 10/17/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RNAZ Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

11 days ago - By: Benzinga

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

11 days ago - By: Stocktwits

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset

11 days ago - By: Benzinga - Mentions: XTLB ESPR KPTI XBIO ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

11 days ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

5 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

6 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

6 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

6 months ago - By: Stocktwits

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside

6 months ago - By: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

6 months ago - By: TransCode Therapeutics, Inc.

News Image

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

6 months ago - By: Zacks Investment Research

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy